推荐产品
等级
certified reference material
质量水平
形式
liquid
特点
Snap-N-Spike®/Snap-N-Shoot®
包装
ampule of 1 mL
制造商/商品名称
Cerilliant®
浓度
1.0 mg/mL in methanol
技术
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
应用
clinical testing
格式
single component solution
储存温度
−20°C
SMILES字符串
CCCC(CCC)C(O)=O
InChI
1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
InChI key
NIJJYAXOARWZEE-UHFFFAOYSA-N
基因信息
human ... ALDH5A1(7915)
一般描述
经认证的加标溶液®适用于临床毒理学、法医分析、尿液药物检测、处方监测或药物研究中的LC/MS或GC/MS应用。丙戊酸是一种抗癫痫药和情绪稳定剂，以Depakote®，Valparin或Stavzor®等商品名出售。该药物被处方用于治疗癫痫、躁郁症、偏头痛和抑郁症。
应用
- The prenatal use of agmatine prevents social behavior deficits in VPA-exposed mice by activating the ERK/CREB/BDNF signaling pathway: This study explores the neuroprotective effects of agmatine against Valproic acid-induced behavioral deficits in mice, highlighting Valproic acid′s role in epigenetic modifications and its potential use in developmental neurotoxicology research (Chen et al., 2024).
法律信息
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Depakote is a registered trademark of Sanofi S.A.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Stavzor is a registered trademark of Noven Therapeutics, LLC
警示用语：
Danger
危险分类
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
靶器官
Eyes,Central nervous system
WGK
WGK 2
闪点(°F)
49.5 °F
闪点(°C)
9.7 °C
法规信息
危险化学品
Matthew D Sztajnkrycer
Journal of toxicology. Clinical toxicology, 40(6), 789-801 (2002-12-12)
Acute valproic acid intoxication is an increasing problem, accounting for more than 5000 calls to the American Association of Poison Control Centers in 2000. The purpose of this paper is to review the pharmacology and toxicology of valproic acid toxicity.
Emily C Bell et al.
Human psychopharmacology, 20(6), 415-424 (2005-08-18)
Previous functional imaging studies have shown altered brain activity during cognitive task performance in bipolar patients. However, the fact that these patients are often on medication makes it unclear to what extent these changes reflect treatment effects. This study aims
P C Ho et al.
The pharmacogenomics journal, 3(6), 335-342 (2003-11-05)
The present study investigated the effect of cytochrome P450 2C9 (CYP2C9) genetic polymorphism on the biotransformation of valproic acid (VPA) to its hepatotoxic metabolite, 4-ene-VPA, and compared that to the formation of the inactive 4-OH-VPA and 5-OH-VPA. cDNA-expressed CYP2C9(*)2 and
Wolfgang Löscher
CNS drugs, 16(10), 669-694 (2002-09-25)
Since its first marketing as an antiepileptic drug (AED) 35 years ago in France, valproate has become established worldwide as one of the most widely used AEDs in the treatment of both generalised and partial seizures in adults and children.
Jakob Christensen et al.
JAMA, 309(16), 1696-1703 (2013-04-25)
Valproate is used for the treatment of epilepsy and other neuropsychological disorders and may be the only treatment option for women of childbearing potential. However, prenatal exposure to valproate may increase the risk of autism. To determine whether prenatal exposure
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门